Indivior Share Discussion Threads

[genierub] 27/11/2020 12:28

This is not going to bounce. If anything it will go much further South. They are trying to kill the company off with the damage claim that doubles the MCAP

[babbler] 27/11/2020 12:17

Trying to bounce

[steeplejack] 27/11/2020 12:00

The press will have a field day,two British companies claiming and counter claiming,one the offspring of the other,it's actually pretty lightweight.

[steeplejack] 27/11/2020 11:57

Perhaps but any case will rumble on for years.It's just that uncertainty will once again stalk the shares.This statement has been put out in a blind panic by all accounts and the market has reacted accordingly.

[dealy] 27/11/2020 11:57

This is a highly unusual move. RB are opening themselves up for litigation here

[babbler] 27/11/2020 11:56

Last time this fell to 28p from same open area on litigation news. Careful.

[davidlloyd] 27/11/2020 11:54

They want them back now that US issue is sorted is my take on it....
DL

[waldron] 27/11/2020 11:53

Price (GBX)
76.55 -38.47% (-47.85)

Open / Last close
121.60 / 124.40

High / Low
125.00 / 76.05

Bid / Offer
72.15 / 73.00

Special Condition: -
Trading Status: AESP Auction Call
FTSE 250
As at 27.11.20 11:37:15 - All data delayed at least 15 minutes

[babbler] 27/11/2020 11:51

Basically RB want them. This is easiest way.

[steeplejack] 27/11/2020 11:51

Yes,I can't see how they'd survive as an independent company and as such I can't see what RB hopes to achieve.I wonder whether RB didn't suspect that Indivior wasn't taking advice about trying to get money out of RB to pay some of their fine and RB thought it'd get in the first punch.I think Indivior is now very vulnerable to a bid.Litigation with the likes of RB isn't like sparring with the DofJ..

[marmar80] 27/11/2020 11:50

Sprry to holders here but can see more than 50 down today

[genierub] 27/11/2020 11:46

If they log this claim and win. INDV is done right? They'd be in the negative.

[steeplejack] 27/11/2020 11:46

I suspect Indivior will make a counterclaim .....at the end of the day only the lawyers will make money.

[dealy] 27/11/2020 11:46

back in 2019 when the DoJ lawsuit was announced the comp never mentionedvthe 3 billion being sought. That ended up in a news article. Only those that saw the news article had the full picture

[steeplejack] 27/11/2020 11:44

Yes bizarre and amateurish.They've left the market hanging for further info.Given the claim was filed two weeks ago and its only just been picked up,you'd think the company might ring their old parent RB and ask for an explanation before screwing up their own share price.

[babbler] 27/11/2020 11:40

If they were you'd think they say something in the rns to stop the huge fall that was coming. That rns was useless. No reassurance or anything.

[steeplejack] 27/11/2020 11:38

Yes that's how I read it but actually I'm not sure that Indivior won't make a counter claim.

[steeplejack] 27/11/2020 11:35

When lawyers start salivating,you know it's time to worry.I can't believe that RB intends to bankrupt its offshoot but we need to know exactly what RB's intention is.

[dealy] 27/11/2020 11:35

it would mean the current shareholders have to pay RB's bill

[babbler] 27/11/2020 11:34

That's basically the whole company

[dealy] 27/11/2020 11:32

it never ends, the drama with this company

[steeplejack] 27/11/2020 11:22

Does the parent wish to strangle her child?RNS Number : 7714GIndivior PLC27 November 2020Claim filed by Reckitt Benckiser Group plcIndivior PLC (the 'Company') has been made aware that a claim was submitted to the Commercial Court in London by Reckitt Benckiser Group plc ('RB') against the Company on November 13, 2020 pursuant to an indemnity contained in the Demerger Agreement entered into between RB and the Company on November 17, 2014. The amount claimed under the submission is GBP1,073,622.580.51.The claim has not been served on the Company and the Company does not have any further details at this time. The Company will assess with its advisors the background and merits to the case and will provide an update in due course.ENDS

[adrian j boris] 23/11/2020 11:47

(INDV)
London Stock Exchange

Share Price: 131.50

Bid: 131.30
Ask: 131.60

Change: 0.40 (0.31%)

[the grumpy old men] 22/11/2020 13:32

RNS Number : 0258G

Indivior PLC

20 November 2020

Indivior PLC - Appointment of Chief Financial Officer

Slough, UK, and Richmond, VA, November 20, 2020 - The Board of Directors of Indivior PLC are pleased to announce the appointment of Ryan Preblick as Chief Financial Officer and Executive Director with immediate effect.

Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group's global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group's largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations.

Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.

Comment by Mark Crossley, Chief Executive Officer

Ryan has proven to be a highly capable leader of our finance organization and has performed strongly in his role as Interim Chief Financial Officer. The Board and I are delighted to confirm his appointment as Chief Financial Officer and Executive Director.

The Company confirms there is no further information to be disclosed pursuant to LR 9.6.13 in connection with Ryan Preblick's appointment.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

Investor Contact :

Jason Thompson, Indivior

Vice President, Investor Relations

[phone]

[e-mail]

Media Contacts :

UK

Tulchan Communications

[phone]

US

[e-mail]

[phone]

-ends-